Myriam Heiman, a renowned molecular neurobiologist and geneticist, has been appointed as the new director of MIT's Picower Institute for Learning and Memory, effective July 1. This appointment marks a significant transition for the institute, as Heiman takes over from Li-Huei Tsai, who has led the institute for 16 years. Heiman's expertise lies in studying neurodegenerative diseases affecting the brain's basal ganglia, including Huntington's and Parkinson's diseases. Her research employs cutting-edge techniques, such as single-cell genomics and a technique she co-invented called translating ribosome affinity purification, to understand the molecular changes leading to cell death in these diseases.
Heiman's appointment is a testament to her exceptional scientific contributions and leadership within MIT. Nergis Mavalvala, dean of the MIT School of Science, praises her research, noting its depth and scope in understanding the vulnerability of specific brain cell types to diseases like Huntington's. Mavalvala believes that Heiman's leadership will be instrumental in the Picower Institute's future endeavors.
Heiman herself expresses her honor and enthusiasm for the new role, emphasizing her commitment to supporting the institute's scientists and trainees in their pursuit of groundbreaking discoveries. Her research has already yielded significant findings, including an in vivo screening of mouse genes that identified a specific gene promoting neuron resilience in Huntington's disease. Additionally, her work has revealed errant immune responses in neurons and blood vessels, contributing to disease progression.
Heiman's research has not only advanced our understanding of neurodegenerative diseases but also explored other psychiatric disorders, such as ALS and frontotemporal dementia. Her collaboration with Manolis Kellis resulted in a cellular atlas of the brain's vasculature, providing valuable insights into the field. Furthermore, her latest research delves into substance use disorders and schizophrenia, showcasing her broad impact in neuroscience.
Heiman's dedication to teaching and mentoring is also recognized. She has received awards for excellence in graduate and undergraduate mentoring, solidifying her commitment to nurturing the next generation of scientists. Beyond MIT, she serves on editorial boards and the scientific advisory board of the Huntington's Disease Foundation, further demonstrating her commitment to advancing research in this field.
In conclusion, Myriam Heiman's appointment as the director of the Picower Institute signifies a new era of leadership and scientific exploration. Her expertise, combined with her dedication to mentorship and research, positions her to make significant contributions to the institute's mission of understanding learning, memory, and related brain functions. As she embarks on this new chapter, the neuroscience community eagerly anticipates the innovative research and discoveries that will emerge under her guidance.
